CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 19 enrolled
Drug / intervention
Eribulin Mesylate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02097238
NCT02097238Phase 2Completed
CompareCT.gov

A Phase II Study of Eribulin (NSC# 707389) in Recurrent or Refractory Osteosarcoma

National Cancer Institute (NCI)·interventional·Posted Mar 27, 2014·Updated May 19, 2020

In Brief

A Phase 2 clinical trial evaluating Eribulin Mesylate and Pharmacological Study for Recurrent Osteosarcoma. Completed, enrolled 19 participants across 119 sites in 2 countries.

Detailed Summary

This phase II trial studies how well eribulin mesylate works in treating patients with osteosarcoma that has come back after treatment (recurrent) or has not responded to treatment (refractory). Microtubule inhibitors, such as eribulin mesylate, may stop or slow the growth of tumor cells by disrupting the cell cycle.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRecurrent Osteosarcoma
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 27, 2014
Enrollment StartAug 1, 2014
Primary CompletionJun 30, 2015
Study CompletionMar 31, 2020
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 12.3 years ago

Interventions

Eribulin Mesylatedrug

Given IV

Pharmacological Studyother

Correlative studies